|
Immunosuppression
|
0.100 |
Biomarker
|
disease |
BEFREE |
Use of Mammalian Target of Rapamycin Inhibitors for Pancreas Transplant Immunosuppression Is Associated With Improved Allograft Survival and Improved Early Patient Survival.
|
31091210 |
2020 |
|
Immunosuppression
|
0.100 |
Biomarker
|
disease |
BEFREE |
Sirolimus, an inhibitor of mammalian target of rapamycin, is used for immunosuppression in kidney transplantation.
|
30548896 |
2019 |
|
Immunosuppression
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The evaluated treatments were cancer-specific interventions (acitretin, imiquimod, photodynamic therapy, nicotinamide, topical diclofenac, and selenium) and immunosuppression regimes (azathioprine, mycophenolate mofetil, calcineurin inhibitors, mammalian target of rapamycin [mTOR] inhibitors, belatacept, induction agents, and withdrawal of calcineurin inhibitors or corticosteroids).
|
31246934 |
2019 |
|
Immunosuppression
|
0.100 |
Biomarker
|
disease |
BEFREE |
Using a case-based presentation, this review focuses on the role of immunosuppression in nonobstetric APS, including B-cell inhibition (rituximab, belimumab, and bortezomib), complement inhibition (eculizumab), mechanistic target of rapamycin inhibition (sirolimus), vascular endothelial cell modulation (defibrotide), statins, and traditional rheumatologic disease-modifying agents (hydroxychloroquine, mycophenolate mofetil, azathioprine, and cyclophosphamide).
|
31808842 |
2019 |
|
Immunosuppression
|
0.100 |
Biomarker
|
disease |
BEFREE |
Mammalian Target of Rapamycin Inhibitors Combined With Calcineurin Inhibitors as Initial Immunosuppression in Renal Transplantation: A Meta-analysis.
|
31343574 |
2019 |
|
Immunosuppression
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thus, while prior work has shown that concomitant belatacept + mTOR inhibitor therapy is effective for maintenance immunosuppression, our preliminary data suggest that everolimus may provide an available means for effecting "rescue" therapy for rejections occurring under belatacept that are refractory to traditional antirejection therapy with corticosteroids and polyclonal antilymphocyte globulin.
|
31415033 |
2019 |
|
Immunosuppression
|
0.100 |
Biomarker
|
disease |
BEFREE |
To examine the therapeutic potential of mTOR inhibition in human mitochondrial disease, four kidney transplant recipients with MELAS/MIDD were switched from calcineurin inhibitors to mTOR inhibitors for immunosuppression.
|
30471880 |
2019 |
|
Immunosuppression
|
0.100 |
Biomarker
|
disease |
BEFREE |
Those changes may impact clinical immunosuppression with evidences suggesting age-specific efficacies of some (CNI and mammalian target of rapamycin inhibitors) but not necessarily all immunosuppressants.
|
31107822 |
2019 |
|
Immunosuppression
|
0.100 |
Biomarker
|
disease |
BEFREE |
Everolimus (EVR) is a mammalian target of rapamycin (mTOR) inhibitor commonly used for immunosuppression (IS) after liver transplantation (LT).
|
31021493 |
2019 |
|
Immunosuppression
|
0.100 |
Biomarker
|
disease |
BEFREE |
This brief overview discusses the beneficial and deleterious effects of mammalian target of rapamycin (mTOR) inhibitors on β cells, and how sirolimus- and everolimus-based immunosuppression have impacted on practices and outcomes of pancreas and islet transplantation.
|
28230643 |
2018 |
|
Immunosuppression
|
0.100 |
Biomarker
|
disease |
BEFREE |
The kinetics of the FoxP3 regulatory T-cell (Treg) population in kidney transplant recipients (KTR) are related to the clinical effect of immunosuppression based on mammalian Target Of Rapamycin inhibitors (mTORi) with/without belatacept (predictive biomarker).
|
30390595 |
2018 |
|
Immunosuppression
|
0.100 |
Biomarker
|
disease |
BEFREE |
The aim of this study was to compare the effect of mTOR inhibitors vs. non-mTOR inhibitor immunosuppression on the incidence, size and complication rate of ovarian cysts in renal transplant recipients.
|
29087803 |
2018 |
|
Immunosuppression
|
0.100 |
Biomarker
|
disease |
BEFREE |
Mammalian target of rapamycin inhibitor-based immunosuppression seems protective against nonmelanoma skin cancer only.
|
30064826 |
2018 |
|
Immunosuppression
|
0.100 |
Biomarker
|
disease |
BEFREE |
To date, limited data from patients given mTOR inhibitor therapy with adequate concurrent immunosuppression, such as reduced-exposure calcineurin inhibitor (CNI) therapy, have not shown an adverse effect on the risk of dnDSA or AMR.
|
28445619 |
2017 |
|
Immunosuppression
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Immunosuppression with the mTOR inhibitor everolimus protects against DSA development after liver transplant.
|
28345271 |
2017 |
|
Immunosuppression
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Regimens based on mammalian target of rapamycin inhibitors, which are known for their antitumoral properties, were used for immunosuppression in both recipients.
|
28480182 |
2017 |
|
Immunosuppression
|
0.100 |
Biomarker
|
disease |
BEFREE |
A calcineurin inhibitor (CNI)-based immunosuppression combined with mammalian target of rapamycin inhibitors (mTORs) seems to be attractive in patients after heart transplantation (HTX) in special clinical situations, for example, in patients with adverse drug effects of prior immunosuppression.
|
28652705 |
2017 |
|
Immunosuppression
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results indicate that conversion to mTORI as primary immunosuppression may be safely accomplished in some pediatric heart transplant patients.
|
28708333 |
2017 |